2022-05-13T15:40:27-07:00 2020-06-30 952076568 Leaf & Cole LLP 2810 Camino Del Rio South Suite 200 San Diego CA 92108 990EZ 2019-07-01 330903864 VACCINE RESEARCH INSTITUTE OF SAN DIEGO VACC 8585813960 3030 BUNKER HILL ST SAN DIEGO CA 92109 JOHN WELSH PHD CEO 2022-05-13 true LATONYA M KNOX P00513874 6192947200 2019 2022-09-23 18:48:47Z X www.vrisd.org X X 100099 X 98519 80 1500 0 1500 0 0 0 100099 50785 7726 49453 25 28028 136017 -35918 71295 35377 X 69396 8428 14366 34384 17256 103780 40050 32485 4673 71295 35377 OUR MISSION IS SCIENTIFIC RESEARCH FOCUSING ON DEVELOPMENT OF PREVENTATIVE AND THERAPEUTIC TREATMENTS FOR BOTH INFECTIOUS (MAALARIA, HEPATITIS B AND C, AND INFLUENZA) AND NON-INFECTIOUS DISEASES (CANCER AND CARDIOVASCULAR DISEASE). Our mission is scientific research focusing on development of preventative and therapeutic treatments for both infectious (malaria, hepatitis B and C, and influenza) and non-infectious diseases (cancer and cardiovascular disease).These studies involve the development of new cancer therapeutics as well as prophylactic and therapeutic vaccines. The goal is to bring to fruition treatments for diseases which have plagued millions of people worldwide and to share these results with the scientific community and the public.To accomplish these goals the VRISD has recruited and will continue to recruit researchers with expertise in Molecular Biology, Pharmacogenomics, Peptide Chemistry, Bioinformatics, Oncology and Immunology. These areas of expertise will allow us to gain an understanding of the host-pathogen and host-tumor interactions as they relate to effective therapeutic design. VRISD scientists are working together for the purpose of eradicating diseases that have eluded researchers and physicians in the past, with the ultimate goal of providing better health for all people worldwide. 107613 107613 JOHN WELSH PHD CEO 40.00 56246 15690 3151 DAVID R MILICH PHD Chairman 2.00 0 RANDY HORTON Director 1.00 0 TERRY DILLMAN Director 1.00 0 false false false false false false false 0 0 0 false 0 0 false CA LEAH JOHNSON 3030 BUNKER HILL ST SAN DIEGO CA 92109 8585813960 false false false false false false false false false false false NONE NONE true X 902931 1031384 767219 450609 98519 3250662 0 0 902931 1031384 767219 450609 98519 3250662 2262737 987925 160 212 224 205 80 881 0 0 3251543 0.30380 0.41000 X Current Year Facts and Circumstances: From 2017 through 2022, VRISD scientists applied for 29 grants from the National Institutes of Health, several from the Department of Defense, and published 45 papers, over topics ranging from Alzheimers disease to prostate cancer. Obtaining funding has been very challenging, and we have not been funded by a public grant since 2017. The organization had hoped that funding from Pellficure Inc. would help bridge the gap between NIH and DOD grants. From the point of view of public benefit, Pellficure Inc. had defined research goals and many of the staff of VRISD worked toward accomplishing those goals, and findings from those studies have been published in publicly accessible literature, thereby accruing public benefit. That work focused on studying the properties of a natural product, plumbagin, that many scientists think may have therapeutic value in treating cancer. Pellficure has a limited intellectual property position regarding plumbagins use in treating prostate cancer. The basic science worked out along the way and published was not performed to support Pellficures property goals. The organization also worked on several projects unrelated to the objectives of Pellficure Inc., including a project to develop a gene signature for the adaptation of metastatic prostate cancer to bone marrow, for which a manuscript is under preparation, and which will serve as a grant application subject in the near future. The organization has also been working on a sequencing technology that was funded through 2017 by the National Cancer Center and will soon be advanced enough to request Phase II funding. While extensive efforts to achieve public funding during the Pellficure period were unsuccessful, the focus and emphasis continues to be to perform basic publicly funded research on important public health problems, and there are several projects in mid-stage development that will develop into NIH, NCI, and DOD grant applications this year, as well as possibly smaller funding sources. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Other Expenses.1005 Travel $18 Other Expenses.1007 Conferences, Conventions, and Meetings $368 Other Expenses.1008 Interest $298 Other Expenses.1009 Depreciation $845 Other Expenses.1012 Insurance $9615 Other Expenses.1 PATENT, LEGAL & TAXES $4559 Other Expenses.2 SUPPLIES $4315 Other Expenses.3 RELOCATION COSTS $3689 Other Expenses.4 TELEPHONE $2676 Other Expenses.5 LICENSES & PERMITS $1040 Other Expenses.6 ANIMAL COSTS $559 Other Expenses.7 BANK & CREDIT CARD FEES $46 Other Assets.1005 Accounts Receivable - Beginning $25720 Accounts Receivable - Ending $12344 Other Assets.1011 Prepaid Expenses and Deferred Charges - Beginning $3752 Prepaid Expenses and Deferred Charges - Ending $0 Other Assets.1 DEPOSITS - Beginning $4912 DEPOSITS - Ending $4912 Total Liabilities.1001 Accounts Payable and Accrued Expenses - Beginning $12594 Accounts Payable and Accrued Expenses - Ending $4673 Total Liabilities.1 OTHER LIABILITIES - Beginning $19891 OTHER LIABILITIES - Ending $0